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The development of an immune response against therapeutic factor VIII is the major
complication in hemophilia A patients. Oligomannose carbohydrates at N239 and/or
N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed
on human dendritic cells, thereby leading to factor VIII endocytosis and presentation to
CD4+ T lymphocytes. Here, we investigated whether altering the interaction of factor
VIII with mannose-sensitive receptors on antigen-presenting cells may be a strategy
to reduce factor VIII immunogenicity. Gene transfer experiments in factor VIII-deficient
mice indicated that N239Q and/or N2118Q factor VIII mutants have similar specific
activities as compared to non-mutated factor VIII; N239Q/N2118Q mutant corrected
blood loss upon tail clip. Production of the corresponding recombinant FVIII mutants
or light chains indicated that removal of the N-linked glycosylation site at N2118 is
sufficient to abrogate in vitro the activation of FVIII-specific CD4+ T cells by human
monocyte-derived dendritic cells. However, removal of mannose-ending glycans at
N2118 did not alter factor VIII endocytosis and presentation to CD4+ T cells by mouse
antigen-presenting cells. In agreement with this, the N2118Q mutation did not reduce
factor VIII immunogenicity in factor VIII-deficient mice. Our results highlight differences
in the endocytic pathways between human and mouse dendritic cell subsets, and
dissimilarities in tissue distribution and function of endocytic receptors such as CD206
in both species. Further investigations in preclinical models of hemophilia A closer to
humans are needed to decipher the exact role of mannose-ending glycans in factor
VIII immunogenicity.
Keywords: hemophilia A, factor VIII, FVIII inhibitors, N-glycosylations, immunogenicity of therapeutic proteins
INTRODUCTION
Five to thirty percent of patients with hemophilia A develop inhibitory anti-factor VIII (FVIII)
antibodies following replacement therapy with therapeutic FVIII (1). The reasons for the elevated
immunogenicity of therapeutic FVIII, as compared to other therapeutic glycoproteins, have
been intensively investigated. These include congenital (2, 3) or bleeding-induced (4) chronic
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inflammation favoring the recruitment and activation of
antigen-presenting cells (APCs) and of immune effectors, and
disequilibrium in regulatory elements of the humoral or cellular
arms of the adaptive immune system (5–7). A mandatory step for
developing an anti-FVIII immune response is the endocytosis of
the exogenously administered FVIII by APCs, such as dendritic
cells (DCs) and macrophages, and the presentation of FVIII-
derived peptides on major histocompatibility complex class II
(MHC II) molecules by APCs to CD4+ T lymphocytes (8, 9).
These last decades, we and others have explored the
mechanisms by which FVIII is endocytosed by APCs either
by targeting endocytic receptors (10, 11) or by masking and
mutating specific amino acid residues in FVIII (11–13). While
there is evidence that residues in the C1 (R2090, K2092, and
F2093) (12) and C2 (R2215 and R2220) (13) domains of FVIII
are involved in the endocytosis of FVIII by human monocyte-
derived DCs (MO-DCs), the nature of the involved endocytic
receptor(s) remains unknown. In vitro experiments using an
excess of mannan demonstrated the importance of mannose-
sensitive receptors for the endocytosis of different FVIII products
by human DCs and for the ensuing presentation of FVIII-derived
peptides to T cells (10, 14). FVIII is a heterodimeric glycoprotein
composed of a heavy chain (A1-a1-A2-a2-B domain) and a
light chain (a3-A3-C1-C2 domain) linked by non-covalent
binding. FVIII contains 20 N-glycosylations that are unequally
distributed over the FVIII molecule: two on the A1 domain,
one on the A3 and C1 domains and the remaining on the
B domain (15). Both plasma-derived FVIII, recombinant full-
length (FL) and B domain-deleted FVIII (BDD-FVIII) have
been reported to contain mannose-ending glycans at positions
N239 and N2118 of the A1 and C1 domain, respectively
(16, 17).
Interestingly, both pre-incubation of DCs with an antibody
toward the macrophage mannose receptor (CD206), and
enzymatic removal of mannosylated glycans on FVIII, lead to
reduced FVIII presentation to a human CD4 + T cell line (10).
Conversely, a recombinant CD206 construct was shown to bind
both the light and heavy chains of BDD-FVIII. Recombinant
FL-FVIII and BDD-FVIII products, commercially available at
the time of the studies, interact with CD206 (10, 18). While
mannose-ending glycans on foreign glycoproteins generally
mediate pathogens recognition and elimination by the immune
system, oligomannose carbohydrates on self-antigens and their
binding to CD206 have been implicated in their catabolism (19).
Here, we studied the involvement of the two mannose-ending
glycans present at positions N239 and N2118 of FVIII in its
immunogenicity in vitro and in vivo.
MATERIALS AND METHODS
Animals
Seven to 12 week-old FVIII exon 16 knock-out C57Bl/6 mice
(from Prof. H. H. Kazazian, University of Pennsylvania School
of Medicine, Philadelphia) (20) and double von Willebrand
factor (VWF)/FVIII deficient mice were used. SureL1 mice are
HLA-A2.1-/HLA-DR1-transgenic, H-2 class I-/class II-knockout
mice (from Dr. Yu-Chun Lone, INSERM, Villejuif, France)
(21). The experimental procedures were approved by the local
ethics committee (Charles Darwin N◦5, Paris, France), and
accreditations have been obtained from the French government
(authorization #2058.04).
Cloning of Wild-Type and Mutant B
Domain-Deleted FVIII for in vivo Gene
Transfer
All clonings and generation of FVIII variants were performed
using a BDD-FVIII coding sequence. Indeed, both FL-FVIII
and BDD-FVIII demonstrate similar levels of immunogenicity
in hemophilia A patients, are endocytosed by human MO-DCs
through mannose sensitive pathway (14), bind to CD206 (18),
and present mannose-exposed sugars at positions N239 and
N2118 (17).
A 4389-base pair fragment was amplified by PCR
from a cDNA encoding a partially BDD-FVIII (12FVIII)
(22) and introduced into the pcDNA3.1/V5-His-TOPO-
TA vector (Thermo Fisher Scientific, Waltham, MA,
United States). 12FVIII contains the 30 N-terminal
amino-acids of the B domain of FVIII, and hence the
N-glycosylation site NAT at position 757–759 (23). The
pcDNA3.1-12FVIII plasmid containing the 12FVIII cDNA
was mutated using the QuickChange II XL mutagenesis
kit (Stratagene, La Jolla, CA, United States). N239 and/or
N2118 were mutated to Q, using the protocol provided
by Stratagene. The wild-type and mutated 12FVIII cDNA
were inserted into the pLIVE vector (Mirus, Madison,
WI, United States).
Cloning, Production and Purification of
Wild-Type and Mutant B Domain-Deleted
FVIII
cDNA encoding human BDD-FVIII (HSQ), containing the 14-
amino acid segment SFSQNPPVLKRHQR in place of the B
domain, cloned in the ReNeo plasmid (24) was used as a
template to generate the FVIII239Q, FVIII2118Q, FVIII2118A,
and FVIII239Q/2118Q mutants by splicing-by-overlap extension
mutagenesis. Presence of the mutations was confirmed by
standard sequencing analysis. BHK-M cells (a kind gift from
Prof P. Lollar, Emory University, Atlanta, Georgia, United States)
were transfected and selected for neomycin resistant clones
using Geneticin- sulfate (500 µg/ml, Sigma Aldrich, St-Louis,
MO, United States). Screening of FVIII producing clones was
performed by detection of the FVIII:antigen (FVIII:Ag) that
refers to the amount of FVIII protein and FVIII:C that refers
to the detectable pro-coagulant activity of FVIII. FVIII:Ag
was detected by a sandwich ELISA using an anti-FVIII light
chain specific monoclonal antibody (mAb) (Clone ESH-8,
BioMedica Diagnostics, Stanford, CA, United States), and a
biotinylated anti-FVIII heavy chain mAb (Clone GMA-8015,
Green Mountain Antibodies, Burlington, United States), as
capture and detection antibodies. FVIII:C was measured by
chromogenic assay (Siemens Healthcare Diagnostic, Marburg,
Germany). For quantification of FVIII in supernatants and
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cell lysates, a sandwich ELISA with ESH8 mAb and the
biotinylated SAF8C polyclonal Ab, as capture and detection
antibodies was performed. The stable expression of wild-type
and mutated FVIII by BHK-M cells, and FVIII purification
were performed as previously described (13). Briefly, the highest
expressing clones for each FVIII was selected (according to
the quantity of FVIII:C produced by 1.106 million cells/ml in
24 h) and were scaled up to near confluency before switching
the medium to serum-free AIM-V medium (Thermo Fisher
Scientific). Medium was collected every 24 h and cells were
replenished with fresh AIM-V medium. FVIII purification
was performed by affinity chromatography on VIII select
column (GE Healthcare, Chicago, IL, United States), followed
by anion-exchange chromatography on HiTrap Resource Q
column (GE Healthcare), as previously described (13). Purified
FVIII was analyzed by 4–12% gradient SDS-PAGE (1 µg
per well) with and without activation by bovine thrombin
(Sigma-Aldrich). A silver staining of the gel was performed
to detect proteins. Specific activity of purified WT and
FVIII mutants were evaluated by chromogenic assay and
absorbance at 280 nm with molar extinction coefficient of
256,300 M−1cm−1.
Cloning and Site-Directed Mutagenesis
of the Light Chain of FVIII
A N2118A mutated light chain of human FVIII was amplified
using appropriate primers from the commercially available cDNA
(pSP64-VIII, ATCC, Manassas, VA, United States). The mutated
light chain fragment was cloned in the pNUT vector, with
the signal sequence of human IgG kappa. The mutated light
chain was produced in DMEM/F12, 5% fetal calf serum (FCS)
by chinese hamster ovary (CHO) K1 stably transfected, and
purified by ion-exchange chromatography. Briefly, a Resource S
column column (GE Healthcare) was equilibrated with 10 mM
histidine-HCl, 5 mM CaCl2, 250 mM NaCl, 0.01% tween 80
(pH 6.0). The culture supernatant in 10 mM MES, 5 mM
EDTA, 0.01% tween 80, pH 6.0 was injected on the column.
The recombinant light chain was eluted with a NaCl gradient,
dialyzed in RPMI for 2 h at 4◦C and quantified by sandwich
ELISA using the human monoclonal anti-C2 conformational
epitope-specific IgG (clone BO2C11, gift from JM Saint Rémy,
Katholieke Universiteit Leuven, Leuven, Belgium), and ESH8
monoclonal antibody. Human recombinant FVIII was used
as a standard. The wild-type light chain was a kind gift
from Dr. E. L. Saenko (Center for Vascular and Inflammatory
Diseases, University of Maryland School of Medicine, Baltimore,
United States) and had been prepared from human FVIII as
described (25).
FVIII Gene Transfer to FVIII-Deficient
Mice and Correction of Bleeding Time
FVIII-deficient mice were injected in the tail vein with pLIVE
plasmid (100 µg) encoding wild-type FVIII (12FVIII) (22),
or the N239Q (12FVIII239Q), N2118Q (12FVIII2118Q) or
N239Q/N2118Q (12FVIII239Q/2118Q) mutants (Figure 1A), in
a large volume (10% of body weight) of 0.9% NaCl within 5 s
(26). Four days later, blood was collected. FVIII:C and FVIII:Ag
were quantified in citrated plasma using a chromogenic assay
(Siemens Healthcare Diagnostics) and an Asserachrom kit (Stago,
Asnières-sur-Seine, France), respectively. On day five, mice were
anesthetized and 3 mm of the distal tail were cut, blood was
collected during 30 min in 50 ml of saline buffer at 37◦C.
Erythrocytes were then pelleted at 1500 g and lysed in H2O.
The amount of released hemoglobin, proportional to blood loss,
was determined by measuring the optical density at 416 nm,
using a standard curve prepared upon lysis of 20 to 100 µl of
mouse blood. The half-life of endogenously produced FVIII was
performed as previously described (27). Briefly, 6 days after the
hydrodynamic injection, mice were injected intravenously with
500 µg of biotin-N-hydroxysuccinimide ester (Pierce, Rockford,
United States) dissolved in saline buffer. Blood was collected
on citrated tubes at different time points after injection and
residual biotinylated FVIII was measured by ELISA, with a
polyclonal anti-human FVIII antibody (SAF8C, Kordia, Leiden,
Netherlands) as capture antibody and streptavidin-HRP for
detection.
FVIII Uptake by Human and Mouse DCs
Human DCs were prepared from purified monocytes (MO)
by CD14 positive selection (Miltenyi Biotec, Paris, France),
cultured in RPMI-1640 (Lonza, Verviers, Belgium), 10% FCS
(Life Technologies, Saint-Aubin, France), supplemented with
GM-CSF (1000 IU/106 cells) and IL-4 (500 IU/106 cells) (Miltenyi
Biotec) (13). Buffy bags from anonymous healthy donors who
gave informed consent were obtained from the Etablissement
Français du Sang (EFS, Rungis, France), in accordance with EFS
guidelines. After 5 days, MO-DC differentiation was validated by
flow cytometry using CD1a and CD14 staining (BD Pharmingen,
San Jose, CA, United States). Murine DCs were generated by
isolation of bone marrow cells from SureL1 mice cultured
for 10 days in RPMI-1640, containing 10% FCS, 50 mM 2-
mercaptoethanol and 200 U/ml murine GM-CSF (Cellgenix
Technology Transfer, Freiburg, Germany) (28). The purity of
bone marrow derived-DCs (BM-DCs) was assessed by flow
cytometry using CD11c staining. FVIII endocytosis by DCs was
detected using the monoclonal anti-FVIII IgG, mAb 77IP52H7,
conjugated to FITC after permeabilization of cells with 0.1%
saponin (14).
Activation of FVIII-Specific T Cells
As a source of FVIII-specific T-cells, the murine FVIII-specific
T-cell hybridoma 1G8-A2, which was generated by immunizing
SureL1 mice with BDD-FVIII (see Supplementary Material)
(18), and the human FVIII-specific T-cell line D9E9 (from
Dr. M. Jacquemin) (29) were used. Five day old MO-DCs
from DRB1∗0101 healthy donors or mitomycin C-treated
splenocytes from SureL1 mice were incubated for 24 h with
the FVIII-specific T-cell hybridoma 1G8-A2 (10,000 MO-DCs
or 200,000 splenocytes for 100,000 T cells) with FVIII in
X-VIVO15 medium (Lonza). Levels of secreted interleukin-
2 (IL-2) were assessed using BD OptEIA mouse IL-2 ELISA
set (BD Biosciences). When the human FVIII-specific T-cell
line D9E9 was used, 5,000 T cells were incubated with
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FIGURE 1 | In vivo production of wild-type and mutated B domain-deleted FVIII lacking the N-glycosylation sites at 239 and 2118. (A) Human BDD-FVIII was
modified by site-directed mutagenesis. The four glycosylation sites are depicted with pin symbols, the full pins represent N239 and N2118, on A1 and C1 domain,
respectively. Four constructs were generated from the 12FVIII sequence: 12FVIII wild-type FVIII (12FVIIIWT), single N239Q mutant (12FVIII239Q), single N2118Q
mutant (12FVIII2118Q) and double mutant FVIII (12FVIII239Q/2118Q). (B) The different pLIVE constructs were injected to FVIII-deficient mice (4 to 11 mice per group)
and blood was recovered after 4 days. The graph depicts as boxes and whiskers the levels of FVIII in plasma, as measured by ELISA (FVIII:Ag, empty bars) and by
functional chromogenic assay (FVIII:C, full bars) using normal human plasma as a standard. Results are a pool of two independent experiments. (C) FVIII-deficient
mice received hydrodynamic injections of pLIVE constructs encoding wild-type (six mice, empty squares) and double mutant FVIII (six mice, empty triangles) FVIII. Six
days later, activated NHS-biotin was injected to each mouse, and residual biotinylated FVIII was measured at indicated time points. Data represent the percentage of
residual biotinylated FVIII (mean ± SEM) quantified at t = 0 (15 min after biotin injection) which was a set at 100% for each mouse. For calculation of half-life, the best
fit was obtained with non-linear regression with two exponential decay (Prism v5.0b, GraphPad Software, Inc.). (D) Four days after hydrodynamic injections of pLIVE
constructs encoding wild-type (five mice, empty squares) and double mutants FVIII (five mice, empty triangles), FVIII-deficient mice were subjected to tail clip
experiments and blood loss was measured. Untreated FVIII-deficient mice (8 mice, empty circles) and wild-type C57BL/6 mice (eight mice, full circles) were used as
controls. Horizontal bars depict medians. Statistical analysis was performed using the non-parametric two-tailed Mann-Whitney U test with a confidence interval of
95%. **P < 0.01; ***P < 0.001; ****P < 0.0001; ns: not significant.
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either MO-DCs from a DRB1∗1501 donor, or with the
FVIII-specific human B-cell line (BO2C11) expressing the
DRB1∗1501/DRB5∗0101 alleles (10,000 cells) (30) in DMEM-
F12 media (Lonza) containing 10% FCS, 20 IU/ml human IL-
2 (Sigma Aldrich), and FVIII fragments for 20 h at 37◦C.
When indicated, MO-DCs or BO2C11 were pre-incubated
30 min at 37◦C with EDTA (5 mM) or mannan (1 mg/ml)
prior to incubation with FVIII and T cells. The production
of interferon-gamma was measured in the supernatants using
the human IFN-gamma Duo Set (R&D Systems, Minneapolis,
Minnesota, United States).
Administration of FVIII and
Characterization of the Anti-FVIII
Immune Response
To evaluate the half-life of recombinant FVIII, FVIII-deficient
mice were administered intravenously with FVIIIHSQ or
FVIII2118Q (100 µl, 10 nM). Plasma was collected at different
time points and FVIII:Ag was measured by ELISA using the anti-
light chain mAb ESH-8, and an anti-FVIII heavy chain mAb
GMA-8015, as coating and detection antibodies, respectively, and
human plasma as a standard (Siemens Healthcare Diagnostics).
To investigate the immunogenicity of recombinant FVIII, FVIII-
deficient mice or VWF/FVIII-deficient mice were injected
intravenously with 0.5 µg FVIIIHSQ or FVIII2118Q, once a week
for 4 weeks. Endotoxin levels in the different recombinant
FVIII were below the accepted threshold (i.e., <0.01 ng
endotoxin/20 g mouse weight) as assessed using the ToxinSensor
Chromogenic LAL Endotoxin Assay Kit (Genscript, Piscataway,
NJ, United States). Blood was collected 5 days after the last
FVIII injection. ELISA plates were coated with FVIII (1 µg/ml,
Recombinate, Baxter, Maurepas, France) overnight at 4◦C. After
blocking with PBS-1% BSA, plasma was incubated for 1 h at
37◦C. Bound IgG were revealed with a HRP-coupled polyclonal
goat anti-mouse IgG antibody (Southern Biotech, Anaheim, CA,
United States) and the OPD substrate. The mouse monoclonal
anti-FVIII IgG mAb6 (from Dr. J. M. Saint-Remy) was used
as a standard. FVIII inhibitors were measured by incubating
heat-inactivated mouse plasma with human standard plasma for
2 h at 37◦C. FVIII residual pro-coagulant activity was measured
by chromogenic assay. Results are expressed in Bethesda titers
(BU/ml) that correspond to the reciprocal dilution of the mouse
plasma that yields 50% residual FVIII activity.
RESULTS
Elimination of the N239 and N2118
Glycosylation Sites Is Compatible With
the Production and Pro-coagulant
Function of FVIII
The cDNA of human recombinant BDD-FVIII (12FVIII)
(22, 23) was modified by site-directed mutagenesis to replace
N239 and/or N2118 with Gln residues and cloned into
the pLIVE vector for hydrodynamic injection experiments
(Figure 1A). Mice injected with pLIVE encoding wild-
type 12-FVIII (12FVIIIWT) produced 370 ± 37 IU/ml
FVIII:C or 373 ± 35 IU/ml FVIII:Ag (mean ± SEM,
Figure 1B). Mice injected with 12FVIII239Q, 12FVIII2118Q or
12FVIII239Q/2118Q-encoding pLIVE produced 52 ± 5, 193 ± 82
and 97± 10 IU/ml FVIII:C, or 25± 2, 200± 72 and 69± 8 IU/ml
FVIII:Ag, respectively, indicating a 2 to 14-fold reduction in
circulation levels of FVIII in mice depending on the constructs.
The half-lives of the endogenously produced FVIII were
evaluated following injection of activated NHS-biotin. FVIII
clearance in FVIII-deficient mice followed a double-exponential
distribution. Half-lives of12FVIIIWT in the fast and slow phases
of elimination were 30 and 260 min, respectively, with 38% of the
FVIII being removed in the fast phase (R2 = 0.91, Figure 1C).
Half-lives of 12FVIII239Q/2118Q in the fast and slow phases of
elimination were 48 and 276 min, respectively, with 50% of the
FVIII being removed in the fast phase (R2 = 0.96). Thus, the
half-lives of12FVIIIWT and12FVIII239Q/2118Q were similar.
We further analyzed the capacity of endogenously produced
12FVIIIWT and 12FVIII239Q/2118Q to correct blood loss in tail
clipping experiments. We first confirmed that wild-type non-
hemophilic mice lose significantly less blood than FVIII-deficient
mice (P = 0.001, Figure 1D). The hydrodynamic injection
of 12FVIIIWT or 12FVIII239Q/2118Q-encoding plasmids into
FVIII-deficient mice corrected blood loss as compared to
untreated mice (P = 0.004 and P = 0.013, respectively).
Interestingly, blood loss in FVIII-deficient mice treated with
the 12FVIII239Q/2118Q construct was not significantly different
from that of wild-type non-hemophilic mice. The fact that
FVIII-deficient mice treated with the 12FVIIIWT-encoding
plasmid bled significantly less than mice treated with the
12FVIII239Q/2118Q-encoding plasmid (P = 0.010) is probably
due to the fact that circulating levels of FVIII were significantly
greater in the former group of mice (373 ± 35 IU/ml,
mean ± SEM, Figure 1B) than in 12FVIII239Q/2118Q-treated
mice (69± 8 IU/ml).
Production and Characterization of
Recombinant FVIII Mutants Lacking the
N239 and N2118 Glycosylation Sites
We then assessed the production of wild-type BDD-
FVIII (FVIIIHSQ) and of the FVIII239Q, FVIII2118Q, and
FVIII239Q/2118Q mutants by stably transfected BHK-M cell
clones. Rates of production of FVIII2118Q (FVIII:C = 0.96 ± 0.23
IU/106 cells/24 h; FVIII:Ag = 120 ± 31 ng/106 cells/24 h;
mean ± SEM, Figures 2A,B, respectively) were not statistically
different from that of FVIIIHSQ (FVIII:C = 1.58 ± 0.49
IU/106 cells/24 h; FVIII:Ag = 204 ± 23 ng/106 cells/24 h).
In contrast, FVIII239Q (0.17 ± 0.03 IU/106 cells/24 h;
29 ± 11 ng/106 cells/24 h) and FVIII239Q/2118Q (0.20 ± 0.03
IU/106 cells/24 h; 64 ± 20 ng/106 cells/24 h) were produced at
rates 8 to 9-fold lower than FVIIIHSQ. The absence of N-linked
glycans at positions 239 and 2118 was validated by comparing
the migration profiles of thrombin-digested purified FVIIIHSQ
and mutants on SDS-PAGE. The lower molecular weight of the
A1 domain of the thrombin-digested FVIII239Q mutant and of
Frontiers in Immunology | www.frontiersin.org 5 March 2020 | Volume 11 | Article 393
fimmu-11-00393 March 26, 2020 Time: 18:12 # 6
Delignat et al. Oligomannose Carbohydrate-Mediated FVIII Uptake
FIGURE 2 | Production of recombinant wild-type and of mutated B domain-deleted FVIII lacking the N-glycosylation sites at 239 and/or 2118. Levels of FVIII:Ag (A)
and FVIII:C (B) produced from BHK-M cells transfected with either the FVIIIHSQ, FVIII239Q, FVIII2118Q, or FVIII239Q/2118Q transgenes were measured by ELISA and
functional chromogenic assay, respectively, and are expressed relative to 1.106 cells. Results are representatives of two independent experiments (mean ± SEM),
n = 7–10 depending on the construct. Statistical comparisons between cells transfected with mutants and FVIIIHSQ were made using the two-tailed Mann-Whitney U
test. (C) SDS-PAGE of FVIIIHSQ, FVIII239Q, and FVIII2118Q with and without exposure to thrombin (FIIa). SC, single chain FVIII; HC, FVIII heavy chain (A1-A2 domains);
LC, FVIII light chain; LCIIa, thrombin-cleaved light chain; A1, A1 domain; A2, A2 domain. Arrow heads depict the deglycosylated A1 domain and light chain for
FVIII239Q and FVIII2118Q, respectively. (D) FVIII activity was measured by functional chromogenic assay and protein concentration was evaluated by absorbance at
280 nm. ‡FVIII239Q and FVIII239Q/2118Q were purified and tested only once. (E) Levels of secreted and intracellular FVIII produced by transfected and untransfected
BHK-M cells were measured after 24 h of culture. Statistical analysis was performed on intracellular levels of FVIII using two-way ANOVA test. The inset depicts the
ratios of secreted versus intracellular FVIII levels. Statistical comparison was assessed by a t-test. Data represent means ± SEM of three independent experiments.
*P < 0.05, **P < 0.01; ***P < 0.001; ns: not significant.
the light chain of the thrombin-digested FVIII2118Q mutant, as
compared to the A1 domain and light chain of the thrombin-
digested FVIIIHSQ confirmed the removal of the N-linked
glycosylation sites (Figure 2C). Besides, the similar molecular
weights observed for the A1 fragment (digested FVIII) in the case
of FVIIIHSQ and FVIII2118Q and the digested light chain of the
FVIII239Q and FVIIIHSQ suggests that site directed mutagenesis
at N239 or/and N2118 did not affect the N-glycosylations at
positions N41 and N1810, respectively. MS analysis would
confirm this observation. Further, a digestion of FVIIIHSQ and
FVIII2118Q with the N-glycosidase F was performed to confirm
that the lower molecular weight of the light chain is due to the
removal of N-linked glycosylation at N2118 and not due to an
uncontrolled proteolytic cleavage (Supplementary Figure S1).
The purified FVIII mutants exhibited specific activities between
4600–6200 IU/mg (Figure 2D) similar to that of FVIIIHSQ.
Furthermore, FVIIIHSQ and the FVIII mutants bound similarly
to immobilized VWF and phosphatidylserine (Supplementary
Figure S2). In order to decipher whether the removal of N239
or/and N2118 affects the production and/or secretion of FVIII,
we measured secreted (supernatant) and intracellular (cell lysate)
FVIII after 24 h of culture of BHK-M cells. Intracellular FVIII
levels were similar for the FVIII239Q, FVIII2118Q and FVIIIHSQ
transfected cells (106 ± 18 ng/106 cells; 195 ± 31 ng/106
cells; 161 ± 28 ng/106 cells, respectively). In contrast, the
intracellular FVIII levels were significantly decreased in the case
of FVIII239/2118Q (70± 9 ng/106 cells/24 h, P< 0.05, Figure 2E).
Comparison of the ratios of secreted versus intracellular FVIII
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levels (Figure 2E, inset) confirms that the N239Q mutation,
either alone or in combination with the N2118Q mutation, is
associated with a hampered secretion of FVIII.
Removal of the N2118 Glycosylation
Abrogates FVIII Presentation by Human
Dendritic Cells
To investigate the potential of the purified FVIIIHSQ and mutants
to be presented to CD4+ T cells by human APCs, we generated a
mouse T-cell hybridoma specific for human FVIII and restricted
to the HLA-DRB1∗01:01 allele, referred to as 1G8-A2. The
activation of 1G8-A2 by FVIII-loaded human MO-DCs from
a HLA-DRB1∗01:01 donor was evaluated by measuring IL-2
secretion. 1G8-A2 is specific for the 2013LFLVYSNKC2022 core
peptide, located in the C1 domain of FVIII light chain (Figure 3A
and Supplementary Figure S3). As previously reported (10),
T-cell activation was drastically reduced when MO-DCs were
pre-incubated with mannan (1 mg/ml) or EDTA (5 mM) prior
to incubation with FVIIIHSQ (Figure 3B). Likewise, removal of
the N2118 glycosylation site resulted in a drastic reduction in
1G8-A2 activation by MO-DCs (39.5 ± 13.4 pg/ml, mean ± SD)
as compared to the use of FVIIIHSQ (572.9 ± 151.9 pg/ml,
P < 0.0001 at 10 nM FVIII, Figure 3C). A different FVIII
variant with an N2118A instead of an N2118Q mutation also
failed to activate 1G8-A2 (35.3 ± 2.1 pg/ml, P < 0.001 as
compared to FVIIIHSQ). In contrast, co-incubation of cells with
the FVIII239Q mutant yielded a significant though less marked
reduction in IL-2 secretion (377.7 ± 96.8 pg/ml, P = 0.002
as compared to FVIIIHSQ). Of note, removal of both N239
and N2118 glycosylation sites did not have an additional effect
on T-cell activation over the removal of the N2118 site alone
(Supplementary Figure S4).
To confirm this observation, we used a different experimental
set-up (different HLA context and using a T-cell line with
a different epitope specificity), in which we compared the
FIGURE 3 | Removal of N-glycosylation at 2118 site alters FVIII light chain presentation by human dendritic cells. (A) Sites of mutations of FVIII and epitope
specificity of FVIII specific T and B cells used in our assays. The figure depicts the structure of human FVIII and the determined sites of N-glycosylation as reported
(15), represented as pins. The nature of oligosaccharides expressed at N239 and N2118 is emphasized: while N2118 carries only Man5- >Man9 oligomannose
carbohydrates, N239 bears an heterogenous population of oligomannose- and complex-type carbohydrates. The epitopes for 1G8-A2, a FVIII-specific mouse
CD4 + T-cell hybridoma (epitope L2012-C2021), D9E9, a human FVIII-specific T-cell line (epitope: I2144-T2161), and for BO2C11, a human FVIII-specific B-cell line
(epitope: 2170–2332) (29, 30) are also depicted. (B) HLA-matched human MO-DCs were pre-incubated with mannan or EDTA prior to incubation with FVIII and
1G8-A2. (C) Activation of 1G8-A2 by FVIII-loaded HLA-matched human MO-DCs with FVIIIHSQ, FVIII239Q, FVIII2118Q, or FVIII2118A was evaluated by quantification of
secreted Il-2 in the supernatant by ELISA. Representative of three experiments (mean ± SD), n = 3. (D–F) Presentation of wild-type or mutant FVIII light chain to
D9E9. Five-day-old MO-DCs (D) or BO2C11 B cells (E) were pre-incubated in medium alone or in the presence of mannan prior to incubation with D9E9 and
wild-type FVIII light chain (LCh). MO-DCs or BO2C11 B cells (F) were incubated with increasing concentrations of mutated N2118A light chain (LCh) in the presence
of D9E9. D9E9 activation was assessed by measuring IFN-gamma in the supernatant by ELISA (mean ± SD), n = 3. Representative of two independent
experiments. Statistical differences were assessed using two-way ANOVA test. **P < 0.01; ***P < 0.001; ****P < 0.0001; ns: not significant.
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presentation of a N2118A mutated or wild-type FVIII light chain
(25) to the HLA-DRB1∗15:01-restricted human D9E9 T-cell
line which is specific for the 2144IIARYIRLHPTHYSIRST2164 C1
domain peptide (29) (Figure 3A). As a source of APCs, we
compared HLA-matched MO-DCs to the human BO2C11 B-cell
line (30). The activation of D9E9 T cells by MO-DCs incubated
with the wild-type FVIII light chain was drastically reduced
in the presence of mannan (Figure 3D), thus reproducing
the data obtained with complete FVIIIHSQ (Figure 3B). In
contrast, BO2C11 B cells activated D9E9 T cells when incubated
in the presence of either wild-type or mutated light chains
(Figures 3E,F), indicating that the absence of the mannose-
ending glycan on the C1 domain does not alter the conformation
of the BO2C11 target epitope on the FVIII C2 domain. It also
confirmed that FVIII light chain endocytosis by BO2C11 B cells,
which is mediated by the B-cell receptor, is insensitive to the
presence of mannan (Figure 3E). Since removal of the glycans
at position N2118 was sufficient to significantly reduce FVIII
presentation to CD4+ T cells, we restricted the rest of the study
to FVIII2118Q.
Mannose-Ending Glycans at Position
2118 do Not Modulate FVIII Endocytosis
and Presentation by Mouse APCs
We have shown earlier that mouse BM-DCs, in contrast to
human MO-DCs, do not endocytose FVIII through mannose-
sensitive endocytosis pathways (31). Here, we compared the
ability of human MO-DCs and HLA-DRB1∗01:01-transgenic
Sure-L1 mouse DCs to endocytose and present FVIIIHSQ and
FVIII2118Q to the FVIII-specific T-cell hybridoma 1G8-A2. While
a 50% reduction of endocytosis by human MO-DCs was observed
with FVIII2118Q compared to FVIIIHSQ (Figure 4A), mouse BM-
DCs internalized FVIIIHSQ, and FVIII2118Q in a similar manner
(Figure 4B). Likewise, mouse splenic APCs activated 1G8-A2
in a similar manner irrespective of the source of FVIII used:
FVIIIHSQ or FVIII2118Q (Figure 4D) whereas only around 10%
of T-cell activation by human MO-DCs was measured with
FVIII2118Q (Figure 4C).
The Absence of N2118 Mannose-Ending
Glycan Does Not Reduce FVIII
Immunogenicity in Mice
We then investigated the consequence of removing the N2118
glycosylation site on FVIII immunogenicity in FVIII-deficient
mice. First, we confirmed that kinetics of FVIII elimination
in both the slow and fast phases did not differ statistically
between FVIIIHSQ and FVIII2118Q (Figure 5A), confirming
the observations obtained with the endogenous expression of
12FVIII239Q/2118Q (Figure 1C).
FVIII-deficient mice were injected with 10 nM FVIII2118Q
or FVIIIHSQ once a week for 4 weeks, and anti-FVIII IgG and
inhibitory titers were measured in serum. The anti-FVIII IgG
titers were similar whether mice were treated with FVIII2118Q
or FVIIIHSQ (17362 ± 9632 AU versus 18758 ± 3166 AU,
respectively, mean ± SEM, Figure 5B). Likewise, the inhibitory
titers in the serum of FVIII2118Q-treated mice were similar to
that in the serum of FVIIIHSQ-treated mice (810 ± 527 BU/ml
versus 639 ± 455 BU/ml, respectively, Figure 5C). Next, we
investigated the immunogenicity of FVIII2118Q and FVIIIHSQ
in the absence of VWF in double FVIII/VWF-deficient mice.
As seen in the case of FVIII-deficient mice, neither anti-FVIII
IgG titers nor inhibitory titers differed between double deficient
mice treated with FVIIIHSQ (2712 ± 2599 AU; 174 ± 195
BU/ml, Figure 5D) or FVIII2118Q (3979 ± 4384 AU; 180 ± 175
BU/ml, Figure 5E). Taken together, our results indicate that
oligomannose carbohydrates at N2118 do not play a major role
in FVIII immunogenicity, at least in mice.
DISCUSSION
Missense mutations in 580 (42%) of the 1384 amino acids that
encompass activated FVIII lead to moderate, mild or severe
hemophilia A (HAMSTeRS database November 2016)1. This
illustrates the critical relationship between the structure and
function of proteins in general, and of FVIII in particular,
which prompted us to estimate the repercussion of removing
N-glycosylation sites of FVIII on its pro-coagulant activity. The
recombinant FVIII239Q/2118Q demonstrated specific activity
similar to that of its respective non-mutated counterpart.
Accordingly, 12FVIII239Q/2118Q protected mice from
experimentally induced blood loss, and FVIII239Q/2118Q bound
normally to VWF and phosphatidylserine. These observations
indicate that removal of oligomannose carbohydrates at N239
and N2118 does not alter the pro-coagulant activity of FVIII.
Circulating levels of 12FVIII in vivo and levels of production
of FVIIIHSQ in vitro were similar or 2-fold lower when the
molecules were mutated at N2118 and 9 to 14-fold lower when
mutations were located at N239. In support of our data, Wei
et al. have shown that, in contrast to mutation at N2118,
mutation at N239 drastically reduces FVIII production (32).
At the cellular level, the efficient transport of FVIII from the
endoplasmic reticulum (ER) to the Golgi apparatus requires the
interaction of FVIII with the mannose-binding lectin LMAN1
(33). The interaction of FVIII with the carbohydrate recognition
domain of LMAN1 implicates either high mannose-containing
N-linked glycosylations, or protein-protein interactions (34). Our
observation of a low ratio of secreted versus intracellular FVIII
in the case of FVIII239Q and FVIII239/2118Q suggests an essential
role for the N239 glycan in FVIII export. Comparatively, the
N2118 glycan plays a negligible role in FVIII production and
secretion. We hypothesize that removal of the N239 glycosylation
site, which is highly conserved among orthologous FVIII
molecules (32), synergizes with the absence of N-glycosylation
sites of the B-domain that is missing in FVIIIHSQ and 12FVIII,
resulting in inefficient intracellular transport of FVIII. Of note,
the in vivo half-life of 12FVIII was not affected by the removal
of the 239 and 2118 N-glycosylation sites. Accordingly, the
half-lives of recombinant FVIIIHSQ and FVIII2118Q were also
similar. Taken together, our data suggest that the oligomannose
carbohydrates at N239 and N2118 of FVIII, that mediate binding
1http://www.factorviii-db.org/
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FIGURE 4 | Removal of N-glycosylation at 2118 does not alter FVIII presentation by mouse APCs. (A,B) Immature human MO-DCs (A) or mouse BM-DCs (B) were
incubated with FVIIIHSQ or FVIII2118Q (20 nM) for 1 h. Internalized FVIII was detected by fluorescence-activated cell sorting (FACS) with LSR II and FACSDiva
software. Results are expressed as the percentage of median fluorescence intensity (MFI), wherein 100% corresponds to the MFI obtained with wild-type FVIII
(FVIIIHSQ). (C,D) The activation of 1G8-A2 by FVIII-loaded (10 nM) HLA-matched human MO-DCs (C) or splenocytes from SURE-L1 mice (D) was evaluated. IL-2
produced by the activated T cells was measured in the supernatant after 24 h. Mean ± SD of three independent experiments. Statistical analysis was performed
using two-tailed, unpaired t-test. *P < 0.05; ****P < 0.0001; ns: not significant.
to CD206 expressed on human macrophages and dendritic
cells (10, 18), and to CLEC4M expressed on human liver and
lymphatic sinusoidal endothelial cells (35), or to the soluble
lectin Galectin-1 (36) are not involved in FVIII catabolism,
at least in mice.
The first step of the primary immune response to therapeutic
FVIII is its uptake by APCs. Our earlier work had documented
the importance of mannose-ending glycans on FVIII for its
recognition and internalization by MO-DCs, used as a model
of APCs, and its subsequent presentation to CD4+ T cells
(10). The phenomenon was true for both full-length and
BDD-FVIII, thus highlighting the contribution of mannose-
ending glycans outside the B domain for FVIII recognition
by human APCs (10, 14). In humans, the presence of high
mannose glycans is not frequent on secreted proteins (37). The
deliberate mannosylation of non-self-antigens has been shown
to enhance their endocytosis by human DCs and subsequent
presentation to antigen-specific T lymphocytes (38, 39). Indeed,
human DCs express several endocytic C-type lectin receptors,
including CD206, DC-SIGN and dectin 2, which bind exposed
mannose residues on glycoproteins through their carbohydrate
recognition domains (40, 41). Interestingly, CD206 is not only
expressed by in vitro derived DCs, but also by some subsets
of DCs in the skin, tonsils and blood (42). The present work
demonstrates the prevalent role of mannosylated glycans at
N2118 in mediating FVIII uptake by MO-DCs, in the context of
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FIGURE 5 | Removal of 2118 mannose ending glycans does not modulate FVIII immunogenicity in FVIII-deficient mice, neither in double VWF/FVIII-deficient mice.
(A) Half-life of wild type and N2118Q mutated FVIII. FVIIIHSQ and FVIII2118Q were administered to FVIII-deficient mice and the residual FVIII:Ag was measured at
different time points (n = 6 mice per time point) using a sandwich ELISA. The data is plotted as percentage of initial FVIII activity (measured 5 min after administration)
versus time (mean ± SEM). Representative of two independent experiments. Inset. The slow and fast phases of FVIII clearance were determined by fitting the data to
a two phase decay curve. The immunogenicity of FVIII2118Q was evaluated in FVIII-deficient mice: (B,C), seven mice for both FVIIIHSQ and FVIII2118Q group and
VWF/FVIII double-deficient mice; (D,E) 8 and 6 mice for FVIIIHSQ and FVIII2118Q group, respectively. One week after the fourth injection, blood samples were
collected and anti-FVIII IgG titers (B,D) quantified using a purified mouse monoclonal anti-FVIII IgG (Mab6) as a standard. Results are expressed in arbitrary units
(AU). Inhibitory titers toward FVIII (C,E) were measured by chromogenic assay. Statistical analysis was performed using the non-parametric two-tailed Mann-Whitney
U test. ns, not significant.
the absence of the heavily glycosylated B domain. Mutations of
N239 had only a marginal effect on T-cell activation by MO-DCs,
which may relate to the fact that glycans at N239 contain high-
mannose, as well as hybrid and complex structures, while glycans
at N2118 exclusively contain high-mannose structures (Man 5-9)
(15–17).
We and others have recently documented the crucial role
played by charged residues in the C1 and C2 domains of FVIII for
its recognition and endocytosis by MO-DCs (11, 13). Mutation
to alanine residues of R2215 and R2220 in the protruding loops
of the C2 domain of FVIIIHSQ (referred to as FVIIIR2215−20A)
as well as of R2090, K2092 and F2093 in the protruding loops
of C1 (referred to as FVIIIC1) independently reduced FVIII
endocytosis by ≥50% and presentation to T cells by ≥75%.
Importantly, FVIIIR2215−20A and FVIIIC1 contain the N-linked
high-mannose carbohydrates at position N2118. Conversely,
FVIII2118Q contains the native amino acids at positions 2092,
2093, 2090, 2215 and 2220, but is not presented to T cells by MO-
DCs. These results point toward a critical role played by the C
domains, and particularly the C1 domain, in the recognition and
internalization of FVIII by MO-DCs. They also suggest that the
engagement of the three FVIII entities – charged residues in the
C1 domain, charged residues in the C2 domain and glycans at
N2118, is required for FVIII uptake, and pave the way toward the
identification of the surface receptors involved in the process.
Removal of the N-linked glycosylation site at position 2118
did not reduce the immunogenicity of FVIII in FVIII-deficient
mice. This is reminiscent of the lack of reduced immunogenicity
of the FVIIIR2215−20A and FVIIIC1 in hemophilic mice, despite
a drastic reduction in endocytosis by DCs (13). Interestingly,
the immunogenicity of FVIIIC1 was reduced as compared to
that of FVIIIHSQ in double FVIII/VWF-deficient mice, thus
highlighting a role for VWF in impairing the potential beneficial
effect of mutations in C1 on a reduction of FVIII immunogenicity
in vivo. We had previously identified CD206 as one of the
receptors implicated in the mannose-sensitive uptake of FVIII
by MO-DCs. The activation of T cells was partially blocked
when MO-DCs and FVIII were incubated in the presence of an
anti-CD206 antibody, and FVIII was demonstrated to interact
with soluble and immobilized CD206 (10). Importantly, the
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interaction between FVIII and CD206 was inhibited in a dose-
dependent manner by VWF (43). A role for endogenous VWF
in preventing the reduction of FVIII2118Q immunogenicity in
FVIII-deficient mice is, however, not probable owing to the fact
that there was no reduction in FVIII2118Q immunogenicity in
double FVIII/VWF-deficient mice.
The mutation of charged residues in the C1 and C2 domains
inhibits endocytosis both by human MO-DCs and by mouse
BM-DCs (12, 13). In contrast to human MO-DCs, however,
mouse BM-DCs do not internalize FVIII through mannose-
sensitive pathways (31). Accordingly, FVIII2118Q and FVIIIHSQ
were captured and presented to a similar extent to T cells
when mouse BM-DCs or splenic APCs were used. Of note,
we observed, as reported previously, that CD206 is expressed
by mouse macrophages from the red pulp of the spleen
(44), and by a subset of mouse splenic dendritic cells (45)
that are present in freshly isolated splenocytes from Sure-L1
mice (data not shown), while in human spleen CD206 has
been reported to be expressed by lining venous sinus cells
and not by macrophages (46, 47). Overall, the organ-specific
expression of C-type lectin receptors is different between mice
and human (48). This is of importance in view of the fact
that we have previously shown the accumulation of exogenously
administered FVIII at the level of metallophilic macrophages in
the marginal zone of the spleen of FVIII-deficient mice (49).
The identification of preclinical animal models that better mimic
the distribution of C-type lectin receptors in the human is
necessary to confirm the reduced immunogenicity of FVIII2118Q
in vivo, and its potential safety for replacement therapy in patients
with hemophilia A.
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